Lexicon Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LEXICON PHARMS INC, and what generic alternatives to LEXICON PHARMS INC drugs are available?
LEXICON PHARMS INC has one approved drug.
There are three US patents protecting LEXICON PHARMS INC drugs.
There are seventy-one patent family members on LEXICON PHARMS INC drugs in thirty-three countries and twelve supplementary protection certificates in eleven countries.
Summary for Lexicon Pharms Inc
| International Patents: | 71 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Lexicon Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 7,781,577 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | 7,781,577 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | 8,217,156 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | 8,476,413 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 8,476,413 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Lexicon Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 106048 | ⤷ Subscribe |
| Israel | 197836 | ⤷ Subscribe |
| Taiwan | I499414 | ⤷ Subscribe |
| South Africa | 201100175 | ⤷ Subscribe |
| South Korea | 20150002889 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lexicon Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2089361 | 132019000000113 | Italy | ⤷ Subscribe | PRODUCT NAME: SOTAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZYNQUISTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1363, 20190430 |
| 2089361 | CA 2019 00042 | Denmark | ⤷ Subscribe | PRODUCT NAME: SOTAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1363 20190430 |
| 2089361 | 122019000077 | Germany | ⤷ Subscribe | PRODUCT NAME: SOTAGLIFLOZIN, ODER EIN PHARMAZEUTISCH ZULAESSIGES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1363 20190426 |
| 2089361 | 2019/044 | Ireland | ⤷ Subscribe | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/19/1363 20190430 |
| 2089361 | 301003 | Netherlands | ⤷ Subscribe | PRODUCT NAME: SOTAGLIFLOZIN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1363 20190430 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
